Sarcoma / SARC (TCGA)

Overview

SARC is the TCGA cohort identifier for sarcoma (predominantly soft tissue and bone sarcomas). The closest OncoTree parent is SARCNOS (Sarcoma, NOS). The TCGA SARC cohort is a heterogeneous collection of multiple sarcoma subtypes including leiomyosarcoma, liposarcoma, synovial sarcoma, and dedifferentiated liposarcoma.

Cohorts in the corpus

  • TCGA SARC cohort: included as one of 33 cancer types in the pan-cancer fusion landscape study; subset of the PanCancer Atlas (sarc_tcga_pan_can_atlas_2018).

Recurrent alterations

  • Pan-cancer fusion study (9,624 TCGA samples) identified SARC as unique in harboring both TP53 fusions and TP53 point mutations (unlike most cancer types where one mechanism predominates); druggable fusions annotated across 29 cancer types including SARC PMID:29617662.

Subtypes

  • Leiomyosarcoma (LMS), dedifferentiated liposarcoma (DDLS), liposarcoma (LIPO), synovial sarcoma (SS), malignant peripheral nerve sheath tumor (MPNST), undifferentiated pleomorphic sarcoma (UPS), and others in the TCGA SARC cohort.

Therapeutic landscape

No drug-specific findings for SARC reported in the current corpus.

Sources

  • PMID:29617662 — Pan-cancer fusion landscape (Gao et al., 2018)

This page was processed by crosslinker on 2026-05-15.